The Digest’s 2024 Multi-Slide Guide to Novonesis, the Investment Perspective
by Jim Lane (Biofuels Digest) A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors?